FABP1 and diabetes mellitus: Administration of apigenin reduced the CD38 expression and mitochondrial oxidative stress in diabetic kidneys, resulting in improved diabetes-induced renal injuries, such as tubulointerstitial fibrosis, tubular damage, inflammation, and urinary albumin/L-FABP excretion.